Natixis Advisors LLC Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Natixis Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 29.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,253 shares of the biopharmaceutical company's stock after purchasing an additional 13,616 shares during the period. Natixis Advisors LLC's holdings in Catalyst Pharmaceuticals were worth $1,237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter worth about $200,000. Intech Investment Management LLC purchased a new stake in Catalyst Pharmaceuticals in the 3rd quarter worth about $644,000. Charles Schwab Investment Management Inc. lifted its stake in Catalyst Pharmaceuticals by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company's stock worth $23,215,000 after purchasing an additional 50,804 shares during the last quarter. Cerity Partners LLC lifted its stake in Catalyst Pharmaceuticals by 31.3% in the third quarter. Cerity Partners LLC now owns 28,733 shares of the biopharmaceutical company's stock worth $571,000 after purchasing an additional 6,847 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 2,994 shares during the period. 79.22% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CPRX. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $32.29.

Catalyst Pharmaceuticals Stock Down 0.6 %

Shares of CPRX stock traded down $0.15 on Friday, hitting $24.69. The stock had a trading volume of 937,935 shares, compared to its average volume of 1,113,694. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16. The business has a 50 day moving average price of $22.66 and a 200 day moving average price of $21.81. The company has a market cap of $3.00 billion, a PE ratio of 20.92, a P/E/G ratio of 3.31 and a beta of 0.84.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.